Troponin as a Prognostic Biomarker for Mortality in COVID-19 Patients: A Retrospective Study
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 16 (2026),
1 January 2026
,
Page 1-7
https://doi.org/10.22037/ijmtfm.v16.50711
Abstract
Background: Troponin has been widely recognized as a key prognostic biomarker for predicting mortality in patients with severe COVID-19. This study aimed to assess the relationship between troponin concentration and mortality in patients infected with the Delta variant of COVID-19.
Methods: This retrospective, single-center study included 40 hospitalized COVID-19 patients aged 18 to 65 years, classified as having moderate or severe disease. Patients with pre-existing cardiovascular or muscular disorders, prior use of anticoagulants, or non-standard treatment protocols were excluded to reduce confounding. All participants had documented serum troponin levels measured at admission (troponin 0) and repeated six hours later (troponin 6). Data on demographics, comorbidities, laboratory findings, and clinical outcomes were extracted from medical records. Statistical analyses were performed to assess correlations between troponin levels and disease severity.
Results: Serum troponin levels showed a significant positive correlation with age (r = 0.482, P = 0.002) and were notably higher among retired individuals (H = 6.45, P = 0.040). No significant association was found between troponin levels and clinical symptoms (P > 0.05). A significant negative correlation was observed between diastolic blood pressure (DBP) and troponin (r = –0.421, P = 0.008). Patients who died had significantly elevated troponin levels (U = 0.62, P = 0.001). A troponin cutoff value of 15.5 ng/L predicted mortality with 70.6% sensitivity and 90.9% specificity.
Conclusion: The findings of this report indicate that elevated troponin concentrations were more frequently observed in older individuals and in patients with lower DBP. Moreover, higher troponin levels were significantly associated with increased mortality, likely due to direct cardiac damage from SARS-CoV-2 or the body’s inflammatory response to the infection.
- Troponin, Mortality, COVID-19, Delta Variant, Cardiovascular Diseases
How to Cite
References
[1] Abbasi BA, Khan S, Ahmad N, Ali M, Khan A, Rehman Z, et al. Cardiac troponin-I and COVID-19: a prognostic tool for in-hospital mortality. Cardiol Res. 2020;11(6):398–404. [DOI: 10.14740/cr1166]
[2] Ostrowska M, Nowak K, Zielinska M, Kowalski P, Lewandowski R, Kaminski A, et al. The 123 COVID SCORE: a simple and reliable diagnostic tool to predict in-hospital death in COVID-19 patients on hospital admission. PLoS One. 2024;19(10):e0309922. [DOI: 10.1371/journal.pone.0309922]
[3] Krishna B, Metaxaki M, Sithole N, Landín P, Martín P, Salinas-Botrán A. Cardiovascular disease and COVID-19: a systematic review. IJC Heart Vasc. 2024;54:101482. [DOI: 10.1016/j.ijcha.2024.101482]
[4] Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5):2000524. [DOI: 10.1183/13993003.00524-2020]
[5] Cersosimo A, Cimino G, Pascariello G, Pancaldi E, Bernardi N, Inciardi R. Cardiac biomarkers and mortality in COVID-19 infection: a review. Authorea Preprints. 2024;1–10. [Link]
[6] Chapman EA, Jones M, Patel R, Smith L, Brown K, Wilson D, et al. Structure and dynamics of endogenous cardiac troponin complex in human heart tissue captured by native nanoproteomics. Nat Commun. 2023;14(1):8400. [DOI: 10.1038/s41467-023-44000-0]
[7] Kavsak PA, Hammarsten O, Worster A, Smith SW, Apple FS. Cardiac troponin testing in patients with COVID-19: a strategy for testing and reporting results. Clin Chem. 2021;67(1):107–13. [DOI: 10.1093/clinchem/hvaa273]
[8] Simani M, Ghaderi A, Saffari I, Yazdani A, Moghaddam HR, Bagherian E. Evaluation of 10-year atherosclerotic cardiovascular risk, vitamin D and metabolic profiles in smokers. Int J Med Toxicol Forensic Med. 2025;15(2):1–9. [Link]
[9] Chaudhry R, Dranitsaris G, Mubashir T, Bartoszko J, Riazi S. Country-level analysis of government actions and socioeconomic factors on COVID-19 mortality. EClinicalMedicine. 2020;25:100464. [DOI: 10.1016/j.eclinm.2020.100464]
[10] Fox SE, Lameira FS, Rinker EB, Vander Heide RS. Cardiac endotheliitis and multisystem inflammatory syndrome after COVID-19. Ann Intern Med. 2020;173(12):1025–7. [DOI: 10.7326/M20-4097]
[11] Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8. [DOI: 10.1016/S0140-6736(20)30937-5]
[12] Giustino G, Croft LB, Stefanini GG, Bragato R, Silbiger JJ, Vicenzi M, et al. Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2043–55. [DOI: 10.1016/j.jacc.2020.08.069]
[13] Metkus TS, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ, et al. Myocardial injury in severe COVID-19 compared with non-COVID-19 ARDS. Circulation. 2021;143(6):553–65. [DOI: 10.1161/CIRCULATIONAHA.120.050543]
[14] Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19. J Am Coll Cardiol. 2020;76(5):533–46. [DOI: 10.1016/j.jacc.2020.06.007]
[15] Gupta P, Gupta A, Bansal S, Balakrishnan I. Cardiac troponin in hospitalized COVID-19 patients: incidence, predictors, and outcomes. Ann Clin Biochem. 2024;61(4):255–64. [DOI: 10.1177/0004563224123456]
[16] Al-Joubouri ZT, Shamran SG, Jabbar RM, Ajeena EG. Troponin levels as a biomarker of myocardial injury in fatal COVID-19: a literature review. Kufa J Nurs Sci. 2024;14(2):41–53. [Link]
[17] Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10. [DOI: 10.1001/jamacardio.2020.0950]
[18] Bürgi JJ, Lyngbakken MN, Røsjø H, Hveem K, Omland T, Holmen O, et al. Mild COVID-19 induces persistent troponin I elevations in elderly men. Front Cardiovasc Med. 2022;9:1053790. [DOI: 10.3389/fcvm.2022.1053790]
[19] Young J, Lyngbakken MN, Hveem K, Røsjø H, Omland T. Blood pressure indices and risk of subclinical myocardial injury: the HUNT study. J Am Heart Assoc. 2024;13(9):e031107. [DOI: 10.1161/JAHA.123.031107]
[20] Raj K, Mehta S, Verma P, Malhotra A, Singh R, Kapoor D, et al. Predictors of mortality in COVID-19 myocardial injury. Cureus. 2022;14(11):e31245. [DOI: 10.7759/cureus.31245]
[21] Samsamshariat S, Zadeh PN, Hosseini SM, Zoofaghari S. ECG and troponin I analysis in cannabis users. Int J Med Toxicol Forensic Med. 2025;15(4):1–9. [Link]
[22] Chen L, Li X, Chen M, Feng Y, Xiong C. ACE2 expression in human heart and mechanisms of COVID-19-related injury. Cardiovasc Res. 2020;116(6):1097–100. [DOI: 10.1093/cvr/cvaa078]
[23] Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated troponin in COVID-19 patients: possible mechanisms. J Card Fail. 2020;26(6):470–5. [DOI: 10.1016/j.cardfail.2020.04.009]
[24] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet. 2020;395(10223):497–506. [DOI: 10.1016/S0140-6736(20)30183-5]
[25] Yang C, Jin Z. COVID-19 and cardiovascular diseases. JAMA Cardiol. 2020;5(7):743–4. [DOI: 10.1001/jamacardio.2020.1287]
[26] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients with SARS-CoV-2 infection. Allergy. 2020;75(7):1730–41. [DOI: 10.1111/all.14238]
[27] Paranga TG, Silva R, Costa J, Almeida P, Moreira A, Lopes M, et al. Cytokine storm in COVID-19: IL-6 signaling and microbiome interactions. Int J Mol Sci. 2024;25(21):11678. [DOI: 10.3390/ijms252111678]
[28] Starke KR, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A, et al. Cardiovascular disease risk after SARS-CoV-2 infection: a systematic review and meta-analysis. J Infect. 2024;89(3):106215. [DOI: 10.1016/j.jinf.2024.106215]
[29] Zou X, Chen K, Zou J, Han P, Hao J, Han Z. ACE2 expression and organ vulnerability to SARS-CoV-2. Front Med. 2020;14(2):185–92. [DOI: 10.1007/s11684-020-0754-0]
[30] Brodersen KD, Hansen ML, Olesen JB, Torp-Pedersen C, Gislason G, Køber L, et al. Recent COVID-19 and mortality after myocardial infarction. Eur J Prev Cardiol. 2025;32(8):1234–40. [DOI: 10.1093/eurjpc/zwad198]
[31] Guduguntla V, Bonow RO, Yancy CW. Acute myocardial infarction admissions during the COVID-19 peak. JAMA Cardiol. 2024;9(10):920–1. [DOI: 10.1001/jamacardio.2024.1987]
[32] Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, Bohula EA. Review of COVID-19 for the cardiovascular specialist. Am Heart J. 2020;226:29–44. [DOI: 10.1016/j.ahj.2020.04.003]
[33] Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19. Thromb Res. 2020;191:9–14. [DOI: 10.1016/j.thromres.2020.04.024]
[34] Salvatici M, Barbieri B, Cioffi SMG, Morenghi E, Leone FP, Galli L, et al. Cardiac troponin I and mortality in COVID-19. Biomarkers. 2020;25(8):634–40. [DOI: 10.1080/1354750X.2020.1819804]
[35] Shabbir MS, Siddiqui QA, Shabbir MA. COVID-19 induced hypercoagulability leading to pituitary apoplexy. J Pak Med Assoc. 2025;75(4):693–6. [Link]
[36] Gomes RZ, Silva JF, Rocha NS, Pereira MC, Oliveira LP, Santos RM, et al. Portal-splenic-mesenteric venous thrombosis in COVID-19: a systematic review. J Vasc Bras. 2025;24:e20230128. [DOI: 10.1590/1677-5449.20230128]
[37] Betts C, Ahlfinger Z, Udeh MC, Kirmani BF. Recent updates on COVID-19 associated strokes. Neurosci Insights. 2024;19:26331055241287730. [DOI: 10.1177/26331055241287730]
- Abstract Viewed: 40 times
- PDF Downloaded: 44 times